Current evidence on the efficacy and safety of faecal microbiota transplant for recurrent Clostridium difficile infection is adequate to support the use of this procedure provided that normal arrangements are in place for clinical governance, consent and audit.
Only consider this procedure for a recurrent episode of C. difficile infection in adults who have had 2 or more previous episodes (as outlined in recommendation 1.1.10 in the NICE antimicrobial prescribing guideline on Clostridioides difficile). [23 July 2021]
Clinicians should ensure that a confidential record is kept of the donor and recipient of each faecal microbiota transplant.
NICE encourages further research into faecal microbiota transplant for C. difficile infection, specifically to investigate optimal dosage, mode of administration and choice of donor.